With a modern, EU-GMP–compliant manufacturing line and an experienced technical team, Ampharco U.S.A has completed the technology transfer of Les Laboratoires Servier’s products for production in Vietnam, with the aim of increasing the localization of high-quality medicines and targeting exports to global markets.
On April 16, 2025, the manufacturing and technology transfer agreement for original brand medicines was signed between Les Laboratoires Servier and Ampharco U.S.A Pharmaceutical Joint Stock Company, witnessed by Ms. Emmanuelle Pavilon-Grosser, the Consul General of France.
This marks an important milestone, reflecting recognition by a multinational pharmaceutical group of Ampharco U.S.A’s capability to manufacture products to European quality standards.
Producing original brand medicines transferred from Europe in Vietnam will help raise the localization rate of high-quality medicines and create more opportunities for patients to access high-quality medicines at affordable prices.